Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

114.36 -1.71 (-1.47%)

Streaming Delayed Price Updated: 10:11 AM EST, Mar 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,106,087
Open	115.16
Bid (Size)	114.30 (100)
Ask (Size)	114.38 (100)
Prev. Close	116.07
Today's Range	113.82 - 115.23
52wk Range	73.31 - 125.14
Shares Outstanding	2,531,374,696
Dividend Yield	2.97%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology

Today 9:42 EST

On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a...

Via Finterra

Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗

March 05, 2026

Merck can help stabilize investors' portfolios, whereas ImmunityBio would be a source of volatility.

Via The Motley Fool

Performance

YTD	+7.4%	+7.4%
1 Month	-1.3%	-1.3%
3 Month	+13.4%	+13.4%
6 Month	+36.1%	+36.1%
1 Year	+22.7%	+22.7%

More News

Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era

March 05, 2026

Via Finterra

ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth

March 04, 2026

Via MarketMinute

2 High-Flying Stocks With More Upside to Buy and Hold ↗

March 04, 2026

Via The Motley Fool

IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗

March 03, 2026

Via Stocktwits

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

Via Stocktwits

USDA Deploys $100 Million 'Screwworm Challenge' to Safeguard U.S. Livestock and Dairy Frontier

March 02, 2026

Via MarketMinute

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗

March 02, 2026

Via Stocktwits

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

February 28, 2026

From Merck & Co., Inc

Via Business Wire

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

February 28, 2026

From Merck & Co., Inc.

Via Business Wire

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗

February 28, 2026

Via The Motley Fool

Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety

February 27, 2026

Via MarketMinute

What's going on in today's session: S&P500 movers ↗

February 27, 2026

Via Chartmill

Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag

February 27, 2026

Via MarketMinute

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

February 27, 2026

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

February 27, 2026

From Merck & Co., Inc.

Via Business Wire

Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results

February 26, 2026

Via MarketMinute

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

Via MarketMinute

The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough

February 26, 2026

Via Finterra

United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’

February 26, 2026

Via Finterra

Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance

February 25, 2026

Via MarketMinute

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

Via MarketMinute

FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

February 25, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

February 25, 2026

From Merck & Co., Inc.

Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?

Yes, Merck & Co is publicly traded.

What exchange does Merck & Co trade on?

Merck & Co trades on the New York Stock Exchange

What is the ticker symbol for Merck & Co?

The ticker symbol for Merck & Co is MRK on the New York Stock Exchange

What is the current price of Merck & Co?

The current price of Merck & Co is 114.36

When was Merck & Co last traded?

The last trade of Merck & Co was at 03/06/26 10:11 AM ET

What is the market capitalization of Merck & Co?

The market capitalization of Merck & Co is 289.49B

How many shares of Merck & Co are outstanding?

Merck & Co has 289B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.